Inito, the India-based health tech startup founded by Aayush Rai and Varun AV in 2015, has secured $6M in Series A funding led by Fireside Ventures. The fresh funds will go towards global expansion of Inito’s hormone testing solutions and will bolster research and development efforts for new diagnostic tests. Inito’s fertility monitor enables women to track fertility hormones quickly and conveniently…
Allara, a virtual care platform serving women of reproductive age with chronic hormonal conditions, has announced a $10M Series A funding round led by GV (Google Ventures). Participants in the funding round include Great Oaks Venture Capital, Humbition, Vanterra, Gaingels, and individual investors such as Tom Lee from One Medical and Maggie Sellers. Additionally, Frédérique Dame, GV’s General Partner, will join Allara’s…
Women’s and Men’s Reproductive Health Pharma Company Besins Healthcare, has opened a new hormone production facility in Muel, Spain, bolsteing their global hormone production capacity by a 30%. This milestone is a response to the growing worldwide demand for hormones, particularly concerning late pregnancies and menopause. The opening follows Besins Healthcare’s strategic acquisition of a hormone production site in Drogenbos, Belgium, in…
Mira is a San Francisco-based company that provides healthcare products for more personal, accurate, and reliable home healthcare. Quanovate was founded in late 2015 by a group of scientists, engineers, OBGYN doctors, and business execs to solve the problem of the unavailability of advanced home health testing. The company’s mission is to make home healthcare more personalized and reliable, while empowering people…
Celmatix, a women’s health biotech company focused on ovarian biology, and Aché Laboratórios, a pharmaceutical company based in Brazil, have announced a collaboration to study a recently discovered melatonin receptor agonist. Their joint research aims to explore its potential applications in women’s health, with a primary focus on polycystic ovary syndrome (PCOS). This announcement follows Celmatix’s recent unveiling of its drug program,…
Reproductive and gynecological health has often been a subject surrounded by societal taboos, misconceptions, and general lack of awareness. Despite this, statistical data reveals that approximately one in three individuals will experience a reproductive or gynecological health issue at some stage in their lives. The need for reliable, accessible, and comprehensive healthcare solutions is evident and in my search for such a…
L’Oréal, the global beauty company, has unveiled new research and innovations in skin health at the prestigious World Congress of Dermatology (WCD) held in Singapore this month. The event gathered top dermatologists, scientists, and researchers to explore the latest advancements in the field. Vichy, a brand under L’Oréal Dermatological Beauty (LDB), presented a significant study investigating the effects of hormonal variations on…
May Health, a clinical-stage medical device company focusing on polycystic ovary syndrome (PCOS), presented promising results from the ULTRA-EU and ULTRA-US feasibility clinical trials for its Ovarian Rebalancing treatment at the 39th Annual European Society of Human Reproduction and Embryology (ESHRE) meeting. The trials demonstrated the treatment’s safety and effectiveness in inducing ovulation in women with PCOS-related infertility. The company also received…